Title:
CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE
Document Type and Number:
WIPO Patent Application WO/2021/039945
Kind Code:
A1
Abstract:
The objective of the invention is to provide cross-species anti-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF-beta 1. To obtain the anti-latent TGF-beta 1 antibodies of the invention, anti-latent-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF-beta 1 were screened, and then humanized, and further optimized. The invention also provides combination therapies comprising an anti-latent TGF-beta 1 antibody and one or more immune checkpoint inhibitors, preferably a PD-1 axis binding antagonists.
Inventors:
SHIMADA HIDEAKI (SG)
KANAMORI MASAKAZU (SG)
KOO XING'ER CHRISTINE (SG)
KANAMORI MASAKAZU (SG)
KOO XING'ER CHRISTINE (SG)
Application Number:
PCT/JP2020/032522
Publication Date:
March 04, 2021
Filing Date:
August 28, 2020
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K39/395; C07K16/30; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/13
Domestic Patent References:
| WO2018043734A1 | 2018-03-08 | |||
| WO2017156500A1 | 2017-09-14 | |||
| WO2019045086A1 | 2019-03-07 | |||
| WO2019163927A1 | 2019-08-29 |
Other References:
See also references of EP 4021498A4
Attorney, Agent or Firm:
HARUNA, Masao et al. (JP)
Download PDF: